In silico hippocampal modeling for multi-target pharmacotherapy in schizophrenia
نویسندگان
چکیده
منابع مشابه
Pharmacotherapy for treatment-resistant schizophrenia
Schizophrenia is a disabling mental illness with a lifetime prevalence of 0.7% worldwide and significant, often devastating, consequences on social and occupational functioning. A range of antipsychotic medications are available; however, suboptimal therapeutic response in terms of psychotic symptoms is common and affects up to one-third of people with schizophrenia. Negative symptoms are gener...
متن کاملpharmacotherapy of schizophrenia
traditionally, schizophrenia was considered to be a severe psychiatric disorder, with a chronic course and an unfavorable outcome. throughout history, there has been incidence of schizophrenia, roughly one percent of the population, consistently, in every culture. it is generally acknowledged that schizophrenia has multifactorial etiology, with multiple susceptibility genes interacting with env...
متن کاملREVIEW Pharmacotherapy of Schizophrenia in Germany
The practice of pharmacotherapy of schizophrenia in Germany is based both on clinical experience and research findings. Experience and studies emphasize that neuroleptic medication is severely limited by side effects including acute extrapyramidal syndromes and tardive dyskinesia. Comparing neuroleptic doses in both acute and maintenance therapy have clinicians encouraged to evaluate methods fo...
متن کاملpharmacotherapy of schizophrenia: ploypharmacy approaches
schizophrenia is a debilitating illness, rating as one of the leading causes of lost years of quality of life. the illness imposes a disproportionate burden on patients and their families, healthcare systems and society. pharmacological management is the cornerstone of treatment of schizophrenia, and antipsychotics, both first generation of antipsychotics and second generation of antipsychotics...
متن کاملPersonalised approaches to pharmacotherapy for schizophrenia
Personalised medicine has been defined as the ‘use of genetic or other biomarker information to improve the safety, effectiveness, and health outcomes of patients via more efficiently targeted risk strati fication, prevention, and tailored medication and treatment management approaches’ (Faulkner 2012). It is a novel approach to therapeutic decisionmaking, which has particular relevance and pot...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: npj Schizophrenia
سال: 2020
ISSN: 2334-265X
DOI: 10.1038/s41537-020-00109-0